Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (AZN)
NASDAQ:AZN
AstraZeneca (AZN) Stock Price & Analysis
6,089 Followers
AZN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$59.57 - $80.86
Previous Close$78.71
Volume2.93M
Average Volume (3M)4.30M
Market Cap
$242.40B
Enterprise Value$265.23B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)38.5
Beta0.50
Next Earnings
Jul 25, 2024EPS Estimate
$0.99Last Dividend Ex-Date
Feb 22, 2024Dividend Yield1.8%
Share Statistics
EPS (TTM)2.04
Shares Outstanding3,100,378,676
10 Day Avg. Volume3,375,258
30 Day Avg. Volume4,295,903
Standard Deviation0.06
R-Squared0.19
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-12.86
Price to Sales (P/S)10.40
Price to Cash Flow (P/CF)22.20
P/FCF Ratio27.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.98
Enterprise Value/Gross Profit7.06
Enterprise Value/Ebitda29.20
Forecast
1Y Price Target
$83.80Price Target Upside6.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
AstraZeneca News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive topline results for the DESTINY-Breast06 Phase 3 trial for Enhertu in HR+, HER2 low and HER2-ultralow metastatic breast cancer.
Financial PerformanceAstraZeneca reported financial results that exceeded expectations with total revenues of $12.679bn, surpassing the consensus of $11.840bn by about 7%.
Revenue GrowthAZN management announced new goals to achieve $80 bn in total revenue and launch 20 new medicines by 2030.
Bears Say
Clinical TrialsThe Phase 3 trial for capivasertib in triple negative breast cancer did not meet its primary endpoint, which may affect future growth prospects.
Market PotentialThe market and revenue potential for treating triple negative breast cancer are relatively modest, limiting the impact on financial forecasts.
Regulatory And CompetitionManagement expects challenges from the Inflation Reduction Act and loss of exclusivity for key products, which could negatively impact revenues.
---
Ownership Overview
0.00%
Insiders
7.13% Mutual Funds
1.03% Other Institutional Investors
91.84% Public Companies and Individual Investors
AZN FAQ
What was Astrazeneca Plc’s price range in the past 12 months?
Astrazeneca Plc lowest stock price was $59.57 and its highest was $80.86 in the past 12 months.
What is Astrazeneca Plc’s market cap?
Currently, no data Available
When is Astrazeneca Plc’s upcoming earnings report date?
Astrazeneca Plc’s upcoming earnings report date is Jul 25, 2024 which is in 3 days.
How were Astrazeneca Plc’s earnings last quarter?
Astrazeneca Plc released its earnings results on Apr 25, 2024. The company reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.956 by $0.074.
Is Astrazeneca Plc overvalued?
According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued.
Does Astrazeneca Plc pay dividends?
Astrazeneca Plc pays a Semiannually dividend of $0.96 which represents an annual dividend yield of 1.8%. See more information on Astrazeneca Plc dividends here
What is Astrazeneca Plc’s EPS estimate?
Astrazeneca Plc’s EPS estimate is $0.99.
How many shares outstanding does Astrazeneca Plc have?
Astrazeneca Plc has 3,100,536,100 shares outstanding.
What happened to Astrazeneca Plc’s price movement after its last earnings report?
Astrazeneca Plc reported an EPS of $1.03 in its last earnings report, beating expectations of $0.956. Following the earnings report the stock price went up 5.379%.
Which hedge fund is a major shareholder of Astrazeneca Plc?
Among the largest hedge funds holding Astrazeneca Plc’s share is PRIMECAP Management Co. It holds Astrazeneca Plc’s shares valued at 3B.
---
AstraZeneca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.80 (6.47% Upside)
$83.80 (6.47% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 96%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.03%
12-Months-Change
Fundamentals
Return on Equity
17.29%
Trailing 12-Months
Asset Growth
5.80%
Trailing 12-Months
Company Description
Astrazeneca Plc
Founded in 1992, UK-based AstraZeneca Plc is a leading global pharmaceutical company, which is engaged in delivering life-changing medicines. The company produces and commercializes medicines for cancer, gastrointestinal, cardiovascular, neuroscience, oncology, respiratory and inflammation and other infectious diseases.
---
AZN Company Deck
---
AZN Earnings Call
Q1 2024
0:00 / 0:00
---
AZN Stock 12 Month Forecast
Average Price Target
$83.80
▲(6.47% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+17.52%
reiterated a buy rating 2 months ago
Copying Steve Scala's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +17.52% per trade.
---